Gastroenterology Advisor

Gastroenterology Advisor is a valuable online platform designed for healthcare professionals, offering thorough insights into essential gastroenterology care practices. It also keeps users informed with the latest clinical updates regarding the diagnosis and treatment of various gastroenterological conditions. Key features include: - Daily news updates - In-depth articles covering significant gastroenterology topics - Real-time coverage of conferences - Insights and opinions from experts - Brief drug information sheets - Clinical charts for quick reference - Continuing medical education (CME) opportunities - And much more… Our goal is to provide the latest clinical research findings and evidence-based recommendations to help clinicians make well-informed decisions for their patients.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#546030

United States

#163661

Health/Medicine

#1295

Traffic sources

Monthly visitors

Articles

Early Screening for Celiac Disease Beneficial for Children with Newly Diagnosed T1DM

4 days ago | gastroenterologyadvisor.com | Colby Stong

Early screening for celiac disease (CD) in the emergency department or inpatient setting is beneficial in children with newly diagnosed type 1 diabetes mellitus (T1DM), according to results of a study published in the Journal of Pediatric Endocrinology and Metabolism.
US Liver Disease, Pancreatitis Burden Rose Sharply During COVID-19 Pandemic

1 week ago | gastroenterologyadvisor.com | Colby Stong

The considerable health care burden associated with nonmalignant liver disease and pancreatitis in the United States was particularly significant during the years of the COVID-19 pandemic, with health disparities noted among patients of certain demographics, according to study results published in Clinical Gastroenterology and Hepatology.
Novo Nordisk Partners With Telehealth Platforms to Expand Wegovy Access

1 week ago | gastroenterologyadvisor.com | Diana Ernst

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy® (semaglutide). The Company is working with Hims & Hers Health, Inc, LifeMD, and Ro to offer all doses of Wegovy through Novo’s direct-to-patient program NovoCare Pharmacy.
Oral Semaglutide 25mg Under Review for Chronic Weight Management

1 week ago | gastroenterologyadvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a 25mg oral formulation of semaglutide for chronic weight management in adults with obesity or overweight, with 1 or more comorbid conditions, and to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
Dual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

1 week ago | gastroenterologyadvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 for the treatment of familial adenomatous polyposis (FAP). There are currently no FDA-approved treatments for FAP, an inherited condition characterized by the proliferation of polyps in the colon and/or rectum. TPST-1495 is an oral, dual receptor inhibitor of prostaglandin (PGE2) signaling.
Catheter Salvage Therapy Effective for CLABSIs in Pediatric Short-Bowel Syndrome

1 week ago | gastroenterologyadvisor.com | Jessica Nye

Catheter salvage therapy may be effective for managing central line-associated bloodstream infection (CLABSIs) while preserving central venous access in pediatric patients with short-bowel syndrome (SBS) on long-term total parenteral nutrition (TPN). These study results were presented at Digestive Disease Week (DDW), held from May 3 to 6, 2025, in San Diego, California.
MAFLD Is Not Predictive of Survival in Those With Hepatocellular Carcinoma

1 week ago | gastroenterologyadvisor.com | Colby Stong

Patients with hepatocellular carcinoma (HCC) who are metabolic-associated fatty liver disease (MAFLD)-positive and MAFLD-negative have similar rates of overall survival (OS) and progression-free survival (PFS) after adjusting for confounding factors, according to study results presented at Digestive Disease Week (DDW), held May 3 to 6, 2025, in San Diego, California.
Beyond BMI: Researchers Identify Obesity Subtypes With Distinct GLP-1 Responses

1 week ago | gastroenterologyadvisor.com | Jessica Nye

Some individuals with obesity have discordant phenotypes of rapid gastric emptying coupled with low glucagon-like peptide-1 (GLP-1) synthesis and secretion, according to study results presented at Digestive Disease Week (DDW), held May 3 to 6, 2025, in San Diego, California. Significant phenotypic heterogeneity is observed among patients with obesity, with multiple behavioral phenotypes and energy balance groups identified.
Exploring the Effects of Terlipressin on Patients Hospitalized With HRS-AKI

1 week ago | gastroenterologyadvisor.com | Colby Stong

Among adults hospitalized with hepatorenal syndrome–acute kidney injury (HRS-AKI), more than one-half of those who were non-waitlisted for liver transplantation (NWL) and received terlipressin achieved HRS reversal, according to study results presented at Digestive Disease Week (DDW), held May 3 to 6, 2025, in San Diego, California. Researchers conducted an analysis of data from adults hospitalized with HRS-AKI between September 2022, and October 2024, using the Premier hospital database.
Patients With Diabetes Using GLP-1 RAs at Increased Risk for Adverse Pancreatic Outcomes

1 week ago | gastroenterologyadvisor.com | Colby Stong

Patients with diabetes mellitus (DM) who use GLP-1 receptor agonists (GLP-1 RAs) have an increased risk for acute and chronic pancreatitis, although the risk for all-cause mortality is lower, according to study results presented at the Digestive Disease Week (DDW), held May 3 to 6, 2025, in San Diego, California.